HealthMagazine

AstraZeneca’s Evusheld approved by EU for Covid-19 treatment

AstraZeneca said on Tuesday its long-acting antibody combination treatment for patients with Covid-19, Evusheld, has been approved in the European Union for individuals aged 12 years and older.

London, 20 September 2022 (dpa/MIA) — AstraZeneca said on Tuesday its long-acting antibody combination treatment for patients with Covid-19, Evusheld, has been approved in the European Union for individuals aged 12 years and older.

The European Commission’s approval was based on results from a Phase 3 study of Evusheld, the British-Swedish firm said.

The results showed that one dose of Evusheld provided clinically and statistically significant protection against progression to severe Covid-19 or death in non-hospitalized adults who had had mild-to-moderate symptoms for seven days or less.

Evusheld was granted marketing authorization in the EU for pre-exposure prevention of Covid-19 in adults and adolescents earlier this year, and is already available in majority of countries in Europe.

Back to top button
Close